Correction: VExUS score: optimizing its use in perioperative and critical care management
-
By
-
Pierre-Grégoire Guinot
-
July 3, 2026
-
0 min
By
Pierre-Grégoire Guinot
July 3, 2026
by Pierre-Grégoire Guinot
July 3, 2026
by María Cruz Martín Delgado, Margo M. C. van Mol, Daniele Poole
June 30, 2026
Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.
July 1, 2026